Printed From:

TYPE 2 INFLAMMATION OCCURS IN
~50% TO 84% OF ADULT PATIENTS
WITH ASTHMA1,2

Asthma is a heterogeneous disease encompassing a range of phenotypes and biomarkers3-7

No single biomarker captures the full range of asthma phenotypes, and relying on only
a narrow range of biomarkers may leave Type 2 inflammation suboptimally controlled3-7

Type 2 inflammation can be detected in patients through individual
biomarkers, such as EOS, IgE, and FeNO, or through combinations of
these markers8,9

Is there more to asthma than allergic and eosinophilic phenotypes?

Get a clearer picture of patients with asthma driven by Type 2 inflammation

TAP TO BEGIN

EOS, eosinophils; FeNO, fractional exhaled nitric oxide.

References: 1. Seys SF, Scheers H, Van den Brande P, et al. Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Respir Res. 2017;18(1):39. doi:10.1186/s12931-017-0524-y 2. Jackson DJ, Aljamil N, Roxas C, et al. The ‘T2-low’ asthma phenotype: could it just be T2-high asthma treated with corticosteroids? Thorax. 2018;73(suppl 4):A124-A125 3. Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol. 2015;308(2):L130-L140. 4. Muraro A, Lemanske RF Jr, Hellings PW, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis—PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347-1358. 5. Brusselle GG, Maes T, Bracke KR. Eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19(8):977-979. 6. Albers FC, Müllerová H, Gunsoy NB, et al. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. J Asthma. 2018;55(2):152-160. 7. Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(4):290-300. 8. Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161-175. 9. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Accessed August 31, 2020. https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf